Results 31 to 40 of about 6,463,095 (311)

Progression-free survival rate.

, 2019
Progression-free survival rate.
Sonia Tejada (4023731), Luis Ramos (550823), José Javier Aristu (6808193), Miguel Ángel Idoate (6808184), Paola Anna Jablonska (6808178), Ricardo Diez-Valle (198834), Marta Moreno-Jiménez (6808181), Maria Reyes Garcia de Eulate (6808187), Pablo Domínguez (4023716), Jaime Gállego Pérez-Larraya (842444), Leire Arbea (6686129), Javier Arbizu (6808190)   +11 more
core   +1 more source

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

Acta Oncologica
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen   +10 more
doaj   +1 more source

Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer – a review of the literature from a developing country perspective

Contemporary Oncology, 2016
We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski, Violetta Sulżyc-Bielicka   +1 more
doaj   +1 more source

Progression-free survival and survival estimates for TDM vs. NTDM.

, 2019
Progression-free survival (PFS, blue) and survival (orange) estimates. Estimates from TDM on solid lines; estimates from NTDM on dotted lines. Note: Progression-Free Survival: likelihood of staying in CP with either imatinib or second-generation TKI ...
Philip S. Bernard (8173509), Srinivas Tantravahi (8173512), Gwendolyn A. McMillin (8173506), Robert L. Schmidt (8173518), Kibum Kim (1420720), Brandon S. Walker (8173515)   +5 more
core   +1 more source

Progression-free survival (PFS) and overall survival (OS).

, 2016
Progression-free survival (PFS) and overall survival (OS).
Udi Sadeh Gonik (3157254), Baruch Brenner (432625), Efraim Idelevich (3157263), Amir Abramovich (3157257), Gal Medalia (3157266), Ofer Purim (432618), Limor Amit (275734), Michal Sarfaty (3157260), Yulia Kundel (432617), Aaron Sulkes (432624), Noa Gordon (3157251)   +10 more
core   +1 more source

Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

Hepatology Research, 2015
AbstractAimAlthough sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little is known about a patient's clinical course after treatment. We investigated the effect of post‐progression survival (PPS) and progression‐free survival (PFS) on overall survival (OS) in patients whose advanced HCC was treated by sorafenib.MethodsWe ...
Terashima, Takeshi, Yamashita, Tatsuya, Takata, Noboru, Nakagawa, Hidetoshi, Toyama, Tadashi, Arai, Kuniaki, Kitamura, Kazuya, Yamashita, Taro, Sakai, Yoshio, Mizukoshi, Eishiro, Honda, Masao, Kaneko, Shuichi   +11 more
openaire   +3 more sources

Ovarian Sex Cord Stromal Tumors in Children and Adolescents—The European Standard Clinical Practice Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider, Kris‐Ann Schultz, Nora Schnitzler, Michael Abele, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Ines B. Brecht, Maja Cesen, Andrea Ferrari, Michaela Kuhlen, Malgorzata A. Krawczyk, Ricardo Lopez‐Almaraz, Yves Reguerre, Calogero Virgone, Daniel Orbach   +15 more
wiley   +1 more source

Long Term Clinical Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Single Center Study [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Objectives Few studies have reported long-term follow-up after treatment of gastric mucosaassociated lymphoid tissue (MALT) lymphoma. In this single-center study, we investigated longterm treatment outcomes in patients diagnosed with gastric MALT ...
Seong Hyun Koh, Seung Hyun Yeo, Moo In Park, Kyoungwon Jung, Sung Eun Kim, Won Moon, Seun Ja Park   +6 more
doaj   +1 more source

Progression-free survival of the VS combination

, 2016
Progression-free survival of the VS ...
Oriana Nanni (16186), Helen Charamis (3592043), Khashayar Esfahani (3592046), Emanuela Scarpi (382324), Lawrence C. Panasci (3592037), Cristiano Ferrario (3592034), Ivan Strepponi (2452123), Wilson H. Miller Jr (504574), Adrian Langleben (3592040)   +8 more
core   +1 more source

Progression-free survival between the Collatamp group and the control group.

, 2022
There was no significant difference in the estimated 2-year progression-free survival rate between the two groups (log-rank p-value = 0.092).
Jaeim Lee (11204526), Seong Taek Oh (10208648), Youn Young Park (10208645), Kil-yong Lee (6050867)   +3 more
core   +1 more source